However, current diagnostic testing performs poorly in the early stages of the disease, resulting in needless biopsies and higher healthcare costs.
Our non-invasive ProCare test leverages a novel biomarker for the detection of prostate cancer, hopefully allowing for earlier and more effective treatment.